Standard BioTools Completes SomaLogic Sale to Illumina for $350 Million in Upfront Cash
ByAinvest
Friday, Jan 30, 2026 9:10 am ET1min read
ILMN--
LAB--
Standard BioTools completed the sale of SomaLogic to Illumina for $350 million in upfront cash and up to $75 million in near-term earnout payments. The company will receive up to $425 million in total proceeds, including royalties. With the sale, Standard BioTools estimates a cash and cash equivalents balance of approximately $550 million. The company plans to use this funding to pursue its inorganic growth strategy and achieve positive adjusted EBITDA in 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet